Drug Profile
Taurocholic acid controlled-release - Satiogen Pharmaceutical
Alternative Names: Conjugated bile acids sodium - Satiogen Pharmaceutical; Ox bile extract - Satiogen Pharmaceutical; Taurocholic acid delayed-release - Satiogen PharmaceuticalLatest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator Satiogen Pharmaceuticals
- Developer Mayo Clinic; Satiogen Pharmaceuticals
- Class Antihyperglycaemics; Cholic acids; Obesity therapies; Small molecules
- Mechanism of Action GPBAR1 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 23 May 2022 Satiogen Pharmaceuticals has been acquired by Mirum Pharmaceuticals
- 22 Feb 2022 Phase II development is ongoing USA (Satiogen Pharmaceuticals website, February 2022)
- 15 Sep 2016 Chemical structure information added